Neurocrine Biosciences Stock Price, News & Analysis (NASDAQ:NBIX)

$84.84 +0.26 (+0.31 %)
(As of 02/22/2018 10:06 AM ET)
Previous Close$84.84
Today's Range$83.91 - $87.48
52-Week Range$39.21 - $91.82
Volume845,400 shs
Average Volume992,581 shs
Market Capitalization$7.51 billion
P/E Ratio-52.05
Dividend YieldN/A
Beta0.26

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:NBIX
CUSIP64125C10
Phone+1-858-6177600

Debt

Debt-to-Equity Ratio0.99%
Current Ratio10.20%
Quick Ratio10.20%

Price-To-Earnings

Trailing P/E Ratio-52.0490797546012
Forward P/E Ratio-771.27
P/E GrowthN/A

Sales & Book Value

Annual Sales$161.63 million
Price / Sales46.86
Cash FlowN/A
Price / CashN/A
Book Value$4.17 per share
Price / Book20.35

Profitability

Trailing EPS($1.63)
Net Income$-142,540,000.00
Net MarginsN/A
Return on Equity-43.46%
Return on Assets-21.65%

Miscellaneous

Employees400
Outstanding Shares89,270,000

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Tuesday, February, 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.18 by $0.11. The firm earned $94.52 million during the quarter, compared to the consensus estimate of $94 million. During the same period last year, the business earned ($0.51) EPS. View Neurocrine Biosciences' Earnings History.

When will Neurocrine Biosciences make its next earnings announcement?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Neurocrine Biosciences.

Where is Neurocrine Biosciences' stock going? Where will Neurocrine Biosciences' stock price be in 2018?

14 analysts have issued 12 month price targets for Neurocrine Biosciences' shares. Their forecasts range from $65.00 to $110.00. On average, they expect Neurocrine Biosciences' share price to reach $90.79 in the next twelve months. View Analyst Ratings for Neurocrine Biosciences.

Who are some of Neurocrine Biosciences' key competitors?

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:

  • William H. Rastetter Ph.D., Independent Chairman of the Board (Age 68)
  • Kevin C. Gorman Ph.D., Chief Executive Officer, Director (Age 58)
  • Matt Abernethy, Chief Financial Officer (Age 38)
  • Eric S. Benevich, Chief Commercial Officer (Age 51)
  • Haig P. Bozigian Ph.D., Chief Development Officer (Age 59)
  • Julie Cooke, Chief People Officer
  • Kyle Gano Ph.D., Chief Business Development Officer (Age 44)
  • Dimitri E. Grigoriadis Ph.D., Chief Research Officer (Age 59)
  • Malcolm Lloyd-Smith, Chief Regulatory Officer (Age 61)
  • Eiry W. Roberts M.D., Chief Medical Officer

Who owns Neurocrine Biosciences stock?

Neurocrine Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (5.82%), BlackRock Inc. (5.40%), Franklin Resources Inc. (3.47%), TimesSquare Capital Management LLC (2.68%), Goldman Sachs Group Inc. (2.41%) and HealthCor Management L.P. (1.72%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Who sold Neurocrine Biosciences stock? Who is selling Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was sold by a variety of institutional investors in the last quarter, including HealthCor Management L.P., Deutsche Bank AG, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Candriam Luxembourg S.C.A., Tekla Capital Management LLC, Franklin Resources Inc. and Artal Group S.A.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

Who bought Neurocrine Biosciences stock? Who is buying Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was bought by a variety of institutional investors in the last quarter, including American Century Companies Inc., Millennium Management LLC, Renaissance Technologies LLC, Perceptive Advisors LLC, Allianz Asset Management GmbH, OppenheimerFunds Inc., Mckinley Capital Management LLC Delaware and Frontier Capital Management Co. LLC. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy Neurocrine Biosciences stock?

Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of Neurocrine Biosciences stock can currently be purchased for approximately $84.84.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $7.51 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 El Camino Real, SAN DIEGO, CA 92130-2042, United States. The company can be reached via phone at +1-858-6177600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NBIX)

Community Ranking:  4.2 out of 5 (star star star star)
Outperform Votes:  601 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  722
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neurocrine Biosciences (NASDAQ:NBIX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.94
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $90.79$82.31$78.88$68.25
Price Target Upside: 7.01% upside1.16% upside5.67% upside26.37% upside

Neurocrine Biosciences (NASDAQ:NBIX) Consensus Price Target History

Price Target History for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018Needham & Company LLCReiterated RatingBuy -> Buy$95.00 -> $110.00LowView Rating Details
2/20/2018Leerink SwannBoost Price TargetOutperform$90.00 -> $96.00MediumView Rating Details
2/14/2018Deutsche BankBoost Price TargetBuy$97.00MediumView Rating Details
2/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight -> Overweight$79.00 -> $100.00HighView Rating Details
2/14/2018BarclaysReiterated RatingOverweight$100.00HighView Rating Details
2/14/2018OppenheimerSet Price TargetBuy$95.00 -> $100.00HighView Rating Details
1/5/2018Jefferies GroupBoost Price TargetBuy$105.00MediumView Rating Details
11/3/2017Robert W. BairdReiterated RatingBuy$84.00N/AView Rating Details
11/2/2017BMO Capital MarketsBoost Price TargetPositive -> Outperform$83.00 -> $109.00N/AView Rating Details
11/2/2017CitigroupReiterated RatingBuy$79.00N/AView Rating Details
10/25/2017Piper Jaffray CompaniesReiterated RatingBuy$76.00N/AView Rating Details
8/9/2017CowenReiterated RatingOutperform$60.00 -> $65.00MediumView Rating Details
5/15/2017Bank of AmericaReiterated RatingBuy$70.00MediumView Rating Details
3/7/2017Cantor FitzgeraldReiterated RatingOverweight$80.00N/AView Rating Details
2/16/2017HC WainwrightBoost Price TargetPositive$80.00 -> $100.00N/AView Rating Details
2/10/2017ICAPReiterated RatingOutperform$55.00N/AView Rating Details
1/27/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Earnings History and Estimates Chart

Earnings by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ NBIX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.21)N/AView Earnings Details
2/13/2018Q4 2017$0.18$0.07$94.00 million$94.52 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.49)($0.13)$29.38 million$60.77 millionViewN/AView Earnings Details
8/3/2017Q2 17($0.67)($0.68)$0.61 million$6.34 millionViewListenView Earnings Details
5/9/2017Q1 17($0.67)($0.90)$3.00 millionViewListenView Earnings Details
2/14/2017Q416($0.55)($0.51)$4.55 millionViewListenView Earnings Details
11/2/2016Q316($0.57)($0.43)ViewN/AView Earnings Details
8/3/2016Q2 2016($0.50)($0.46)ViewN/AView Earnings Details
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details
7/29/2015Q2($0.29)($0.28)$0.41 millionViewListenView Earnings Details
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details
4/30/2014Q114($0.19)($0.17)$0.78 millionViewN/AView Earnings Details
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details
5/2/2012($0.01)ViewN/AView Earnings Details
2/8/2012Q4 2011$0.01$0.02ViewN/AView Earnings Details
10/31/2011$0.19$0.56ViewN/AView Earnings Details
7/28/2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011$0.05$0.05ViewN/AView Earnings Details
2/10/2011$0.04$0.05ViewN/AView Earnings Details
10/28/2010Q3 2010$0.05$0.06ViewN/AView Earnings Details
7/28/2010Q2 2010($0.17)($0.09)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.24)($0.20)ViewN/AView Earnings Details
2/3/2010Q4 2009($0.28)($0.22)ViewN/AView Earnings Details
10/28/2009Q3 2009($0.35)($0.21)ViewN/AView Earnings Details
7/29/2009Q2 2009($0.41)($0.37)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.38)($0.38)ViewN/AView Earnings Details
2/3/2009Q4 2008($0.47)($0.75)ViewN/AView Earnings Details
10/28/2008Q3 2008($0.52)($0.46)ViewN/AView Earnings Details
7/30/2008Q2 2008($0.52)($0.55)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.54)($0.55)ViewN/AView Earnings Details
2/5/2008Q4 2007($0.84)($0.71)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Neurocrine Biosciences (NASDAQ:NBIX) Earnings Estimates

2018 EPS Consensus Estimate: $0.00
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.28)($0.22)($0.26)
Q2 20183($0.18)$0.33$0.12
Q3 20183($0.13)$0.01($0.04)
Q4 20183($0.06)$0.43$0.18
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Neurocrine Biosciences (NASDAQ NBIX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.80%
Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ NBIX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Gary A LyonsDirectorSell5,000$84.67$423,350.00View SEC Filing  
2/12/2018Dimitri E GrigoriadisInsiderSell86,368$78.32$6,764,341.76154,717View SEC Filing  
2/9/2018Dimitri E GrigoriadisInsiderSell71,775$77.98$5,597,014.50154,717View SEC Filing  
2/6/2018Kevin Charles GormanCEOSell105,983$80.25$8,505,135.75339,482View SEC Filing  
2/5/2018Gary A LyonsDirectorSell5,000$83.08$415,400.00267,066View SEC Filing  
2/5/2018Haig P BozigianInsiderSell2,262$83.10$187,972.2076,950View SEC Filing  
1/24/2018William H RastetterDirectorSell9,500$90.00$855,000.0034,250View SEC Filing  
1/16/2018Haig P BozigianInsiderSell1,625$79.12$128,570.00View SEC Filing  
1/16/2018Kevin Charles GormanCEOSell3,750$78.89$295,837.50View SEC Filing  
1/3/2018Darin LippoldtInsiderSell1,979$79.36$157,053.44View SEC Filing  
12/28/2017Darin LippoldtInsiderSell15,237$75.00$1,142,775.00View SEC Filing  
12/28/2017Darin LippoldtInsiderSell15,237$75.00$1,142,775.0028,394View SEC Filing  
12/8/2017Darin LippoldtInsiderSell2,955$75.00$221,625.0016,112View SEC Filing  
12/4/2017Darin LippoldtInsiderSell6,279$75.04$471,176.1619,436View SEC Filing  
12/1/2017Gary A LyonsDirectorSell10,000$72.92$729,200.00272,066View SEC Filing  
11/15/2017Darin LippoldtInsiderSell9,900$73.05$723,195.00View SEC Filing  
11/8/2017Dimitri E GrigoriadisInsiderSell30,000$74.58$2,237,400.0077,691View SEC Filing  
11/2/2017Kyle GanoInsiderSell24,818$71.05$1,763,318.9084,596View SEC Filing  
10/2/2017Christopher Flint ObrienInsiderSell6,925$61.04$422,702.0055,898View SEC Filing  
9/6/2017Haig P BozigianInsiderSell26,250$60.00$1,575,000.00144,601View SEC Filing  
9/5/2017Christopher Flint ObrienInsiderSell52,817$57.50$3,036,977.50101,790View SEC Filing  
8/9/2017Dimitri E GrigoriadisInsiderSell15,354$55.00$844,470.00123,045View SEC Filing  
8/4/2017Haig P BozigianInsiderSell22,500$50.00$1,125,000.00154,601View SEC Filing  
7/27/2017Christopher Flint ObrienInsiderSell8,734$50.00$436,700.0057,707View SEC Filing  
5/23/2017Dimitri E GrigoriadisInsiderSell10,000$53.39$533,900.00107,691View SEC Filing  
5/19/2017Malcolm Lloyd-SmithInsiderSell9,960$53.63$534,154.8017,997View SEC Filing  
5/5/2017Corinne H NevinnyDirectorSell5,000$53.98$269,900.0034,603View SEC Filing  
5/2/2017Dimitri E GrigoriadisInsiderSell10,000$55.00$550,000.00117,691View SEC Filing  
5/2/2017Kevin Charles GormanCEOSell21,739$53.23$1,157,166.97354,346View SEC Filing  
5/1/2017Kyle GanoInsiderSell15,000$54.00$810,000.0088,246View SEC Filing  
4/12/2017Haig P BozigianInsiderSell13,065$50.42$658,737.30129,805View SEC Filing  
4/12/2017Kevin Charles GormanCEOSell19,596$50.42$988,030.32332,913View SEC Filing  
2/7/2017Malcolm Lloyd-SmithInsiderSell116$44.61$5,174.76View SEC Filing  
2/6/2017Dimitri E GrigoriadisInsiderSell727$43.13$31,355.51115,756View SEC Filing  
2/6/2017Kevin Charles GormanCEOSell3,010$43.18$129,971.80250,542View SEC Filing  
2/6/2017Timothy P CoughlinCFOSell963$43.14$41,543.82137,961View SEC Filing  
2/3/2017Christopher Flint ObrienInsiderSell1,500$42.50$63,750.0035,044View SEC Filing  
2/3/2017Kevin Charles GormanCEOSell3,125$42.55$132,968.75247,802View SEC Filing  
2/1/2017William H RastetterDirectorSell10,750$42.28$454,510.0025,000View SEC Filing  
1/17/2017Haig P BozigianInsiderSell1,625$40.63$66,023.75114,704View SEC Filing  
1/17/2017Kevin Charles GormanCEOSell3,750$40.65$152,437.50244,677View SEC Filing  
1/17/2017Timothy P CoughlinCFOSell1,750$40.65$71,137.50134,824View SEC Filing  
1/10/2017Christopher Flint ObrienInsiderSell1,750$43.35$75,862.5031,794View SEC Filing  
1/10/2017Kevin Charles GormanCEOSell3,750$43.28$162,300.00240,927View SEC Filing  
11/15/2016Christopher Flint ObrienInsiderSell25,000$52.84$1,321,000.0030,044View SEC Filing  
9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.009,000View SEC Filing  
8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.0055,044View SEC Filing  
8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.0025,555View SEC Filing  
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.0015,464View SEC Filing  
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.0080,044View SEC Filing  
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.4057,788View SEC Filing  
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00105,044View SEC Filing  
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75111,454View SEC Filing  
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00228,077View SEC Filing  
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00131,374View SEC Filing  
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25110,079View SEC Filing  
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00224,952View SEC Filing  
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50129,874View SEC Filing  
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25108,454View SEC Filing  
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50221,202View SEC Filing  
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50128,124View SEC Filing  
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00105,308View SEC Filing  
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00106,829View SEC Filing  
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00217,452View SEC Filing  
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00252,066View SEC Filing  
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.0077,058View SEC Filing  
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.0096,544View SEC Filing  
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50180,952View SEC Filing  
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.0097,874View SEC Filing  
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.0075,433View SEC Filing  
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00177,202View SEC Filing  
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.0096,124View SEC Filing  
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.0022,488View SEC Filing  
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.0094,794View SEC Filing  
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.9676,954View SEC Filing  
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.7596,124View SEC Filing  
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.701,000View SEC Filing  
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.0076,954View SEC Filing  
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.3596,124View SEC Filing  
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Neurocrine Biosciences (NASDAQ NBIX) News Headlines

Source:
DateHeadline
AbbVie, Neurocrine shares rise after positive results for uterine ... - MarketWatchAbbVie, Neurocrine shares rise after positive results for uterine ... - MarketWatch
www.marketwatch.com - February 22 at 8:44 AM
Neurocrine Biosciences Shows Again That Sometimes The Tortoise Wins - Seeking AlphaNeurocrine Biosciences Shows Again That Sometimes The Tortoise Wins - Seeking Alpha
seekingalpha.com - February 22 at 8:44 AM
Neurocrine Biosciences: Q4 Update - Seeking AlphaNeurocrine Biosciences: Q4 Update - Seeking Alpha
seekingalpha.com - February 22 at 8:44 AM
Leerink Swann Weighs in on Neurocrine Biosciences, Inc.s Q1 2018 Earnings (NBIX)Leerink Swann Weighs in on Neurocrine Biosciences, Inc.'s Q1 2018 Earnings (NBIX)
www.americanbankingnews.com - February 22 at 7:52 AM
AbbVie (ABBV) Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids Met Its Primary EndpointAbbVie (ABBV) Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids Met Its Primary Endpoint
www.streetinsider.com - February 21 at 8:47 AM
AbbVie Reports Positive Topline Results From Phase 3 Elagolix StudyAbbVie Reports Positive Topline Results From Phase 3 Elagolix Study
www.nasdaq.com - February 21 at 8:47 AM
AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine FibroidsAbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
finance.yahoo.com - February 21 at 8:47 AM
AbbVie, Neurocrine shares rise after positive results for uterine fibroids drugAbbVie, Neurocrine shares rise after positive results for uterine fibroids drug
finance.yahoo.com - February 21 at 8:47 AM
Neurocrine Biosciences (NBIX) PT Raised to $96.00 at Leerink SwannNeurocrine Biosciences (NBIX) PT Raised to $96.00 at Leerink Swann
www.americanbankingnews.com - February 20 at 8:26 PM
Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Director Sells 5,000 Shares of StockInsider Selling: Neurocrine Biosciences, Inc. (NBIX) Director Sells 5,000 Shares of Stock
www.americanbankingnews.com - February 20 at 6:56 PM
Oppenheimer Reiterates "$100.00" Price Target for Neurocrine Biosciences (NBIX)Oppenheimer Reiterates "$100.00" Price Target for Neurocrine Biosciences (NBIX)
www.americanbankingnews.com - February 18 at 1:36 PM
Neurocrine Biosciences (NBIX) Rating Reiterated by BarclaysNeurocrine Biosciences (NBIX) Rating Reiterated by Barclays
www.americanbankingnews.com - February 18 at 6:54 AM
NBIX: Will File an NDA for Opicapone in 1H19NBIX: Will File an NDA for Opicapone in 1H19
finance.yahoo.com - February 16 at 5:03 PM
Neurocrine Biosciences, Inc. (NBIX) to Post Q1 2018 Earnings of ($0.28) Per Share, Jefferies Group ForecastsNeurocrine Biosciences, Inc. (NBIX) to Post Q1 2018 Earnings of ($0.28) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - February 16 at 7:56 AM
Q1 2018 Earnings Forecast for Neurocrine Biosciences, Inc. Issued By Oppenheimer (NBIX)Q1 2018 Earnings Forecast for Neurocrine Biosciences, Inc. Issued By Oppenheimer (NBIX)
www.americanbankingnews.com - February 16 at 7:56 AM
Jefferies Group Brokers Raise Earnings Estimates for Neurocrine Biosciences, Inc. (NBIX)Jefferies Group Brokers Raise Earnings Estimates for Neurocrine Biosciences, Inc. (NBIX)
www.americanbankingnews.com - February 15 at 3:46 PM
Oppenheimer Analysts Lift Earnings Estimates for Neurocrine Biosciences, Inc. (NBIX)Oppenheimer Analysts Lift Earnings Estimates for Neurocrine Biosciences, Inc. (NBIX)
www.americanbankingnews.com - February 15 at 3:10 PM
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update ... - PR Newswire (press release)Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update ... - PR Newswire (press release)
www.prnewswire.com - February 15 at 8:10 AM
Neurocrine Biosciences (NBIX) Says FDA Provides Guidance on Opicapone, Will File NDA FH19 - StreetInsider.comNeurocrine Biosciences (NBIX) Says FDA Provides Guidance on Opicapone, Will File NDA FH19 - StreetInsider.com
www.streetinsider.com - February 15 at 8:10 AM
Neurocrine Biosciences (NBIX) Given New $97.00 Price Target at Deutsche BankNeurocrine Biosciences (NBIX) Given New $97.00 Price Target at Deutsche Bank
www.americanbankingnews.com - February 14 at 11:12 PM
Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinsons Disease Based on Existing Pivotal Clinical Trial DataNeurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data
finance.yahoo.com - February 14 at 5:13 PM
Neurocrine Biosciences (NBIX) Price Target Increased to $100.00 by Analysts at JPMorgan Chase & Co.Neurocrine Biosciences (NBIX) Price Target Increased to $100.00 by Analysts at JPMorgan Chase & Co.
www.americanbankingnews.com - February 14 at 1:38 PM
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018
finance.yahoo.com - February 14 at 9:37 AM
Neurocrine misses 4Q profit forecastsNeurocrine misses 4Q profit forecasts
finance.yahoo.com - February 14 at 9:37 AM
Neurocrine Biosciences (NBIX) Posts Quarterly  Earnings Results, Misses Estimates By $0.11 EPSNeurocrine Biosciences (NBIX) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS
www.americanbankingnews.com - February 14 at 8:44 AM
Dimitri E. Grigoriadis Sells 71,775 Shares of Neurocrine Biosciences, Inc. (NBIX) StockDimitri E. Grigoriadis Sells 71,775 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock
www.americanbankingnews.com - February 13 at 6:10 PM
Neurocrine Biosciences, Inc. (NBIX) Insider Sells $6,764,341.76 in StockNeurocrine Biosciences, Inc. (NBIX) Insider Sells $6,764,341.76 in Stock
www.americanbankingnews.com - February 13 at 6:10 PM
Neurocrine Biosciences, Inc. to Host Earnings CallNeurocrine Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - February 13 at 3:59 PM
Neurocrine Biosciences, Inc. (NBIX) Given Average Rating of "Buy" by AnalystsNeurocrine Biosciences, Inc. (NBIX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 9 at 1:30 AM
Neurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceNeurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 3:57 PM
Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $8.5 million of SharesNeurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $8.5 million of Shares
finance.yahoo.com - February 8 at 8:28 AM
Neurocrine Biosciences, Inc. (NBIX) Expected to Announce Quarterly Sales of $94.00 MillionNeurocrine Biosciences, Inc. (NBIX) Expected to Announce Quarterly Sales of $94.00 Million
www.americanbankingnews.com - February 8 at 2:08 AM
Haig P. Bozigian Sells 2,262 Shares of Neurocrine Biosciences, Inc. (NBIX) StockHaig P. Bozigian Sells 2,262 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock
www.americanbankingnews.com - February 8 at 12:46 AM
Neurocrine Biosciences, Inc. (NBIX) Director Sells $415,400.00 in StockNeurocrine Biosciences, Inc. (NBIX) Director Sells $415,400.00 in Stock
www.americanbankingnews.com - February 8 at 12:30 AM
Insider Selling: Neurocrine Biosciences, Inc. (NBIX) CEO Sells 105,983 Shares of StockInsider Selling: Neurocrine Biosciences, Inc. (NBIX) CEO Sells 105,983 Shares of Stock
www.americanbankingnews.com - February 8 at 12:10 AM
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial ResultsNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results
www.prnewswire.com - February 6 at 1:28 PM
Neurocrine Biosciences (NBIX) Scheduled to Post Earnings on MondayNeurocrine Biosciences (NBIX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 5 at 3:44 AM
Neurocrine Biosciences (NBIX) Upgraded at BidaskClubNeurocrine Biosciences (NBIX) Upgraded at BidaskClub
www.americanbankingnews.com - January 31 at 10:54 PM
William H. Rastetter Sells 9,500 Shares of Neurocrine Biosciences, Inc. (NBIX) StockWilliam H. Rastetter Sells 9,500 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock
www.americanbankingnews.com - January 26 at 9:14 PM
FY2017 EPS Estimates for Neurocrine Biosciences, Inc. Raised by Zacks Investment Research (NBIX)FY2017 EPS Estimates for Neurocrine Biosciences, Inc. Raised by Zacks Investment Research (NBIX)
www.americanbankingnews.com - January 26 at 6:30 AM
Whats Happening With These Generic Drugs Stocks? -- Medicines, Mylan, Neurocrine Biosciences, and Rigel Pharma - PR Newswire (press release)What's Happening With These Generic Drugs Stocks? -- Medicines, Mylan, Neurocrine Biosciences, and Rigel Pharma - PR Newswire (press release)
www.prnewswire.com - January 23 at 3:36 PM
$94.00 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter$94.00 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter
www.americanbankingnews.com - January 22 at 2:32 AM
 Analysts Anticipate Neurocrine Biosciences, Inc. (NBIX) to Announce $0.11 EPS Analysts Anticipate Neurocrine Biosciences, Inc. (NBIX) to Announce $0.11 EPS
www.americanbankingnews.com - January 20 at 11:26 PM
Neurocrine Biosciences, Inc. (NBIX) Insider Haig P. Bozigian Sells 1,625 SharesNeurocrine Biosciences, Inc. (NBIX) Insider Haig P. Bozigian Sells 1,625 Shares
www.americanbankingnews.com - January 18 at 7:58 PM
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Charles Gorman Sells 3,750 SharesNeurocrine Biosciences, Inc. (NBIX) CEO Kevin Charles Gorman Sells 3,750 Shares
www.americanbankingnews.com - January 18 at 7:34 PM
FY2017 EPS Estimates for Neurocrine Biosciences, Inc. (NBIX) Increased by AnalystFY2017 EPS Estimates for Neurocrine Biosciences, Inc. (NBIX) Increased by Analyst
www.americanbankingnews.com - January 18 at 6:44 AM
Neurocrine Biosciences, Inc. (NBIX) Forecasted to Post Q1 2018 Earnings of ($0.16) Per ShareNeurocrine Biosciences, Inc. (NBIX) Forecasted to Post Q1 2018 Earnings of ($0.16) Per Share
www.americanbankingnews.com - January 17 at 12:00 PM
Neurocrine, Ingrezza Sail Into 2018 - Seeking AlphaNeurocrine, Ingrezza Sail Into 2018 - Seeking Alpha
seekingalpha.com - January 11 at 10:13 AM
FY2017 EPS Estimates for Neurocrine Biosciences, Inc. Increased by Leerink Swann (NBIX)FY2017 EPS Estimates for Neurocrine Biosciences, Inc. Increased by Leerink Swann (NBIX)
www.americanbankingnews.com - January 10 at 6:56 AM
CELG Makes Blockbuster Purchase, MDXG, NBIX On Watch, Busy Year Ahead For ALNY - NasdaqCELG Makes Blockbuster Purchase, MDXG, NBIX On Watch, Busy Year Ahead For ALNY - Nasdaq
www.nasdaq.com - January 8 at 9:30 AM

SEC Filings

Neurocrine Biosciences (NASDAQ:NBIX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neurocrine Biosciences (NASDAQ:NBIX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neurocrine Biosciences (NASDAQ NBIX) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.